Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine

Journal of Cardiovascular Translational Research

Volumn 3, Issue 6, 2010, Pages 704-716

  Povsic, Thomas J ^a   Sullenger, Bruce A ^b   Zelenkofske, Steven L ^c   Rusconi, Christopher P ^c   Becker, Richard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Regado Biosciences   (United States)

Author keywords

Antithrombotic agents; Aptamers; Nucleic acids

Indexed keywords

APTAMER; BLOOD CLOTTING FACTOR 10A; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; PLATELET MEMBRANE GLYCOPROTEIN VI; THROMBIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ANIMAL; BLOOD; BLOOD CLOTTING; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; REVIEW; THROMBOCYTE; THROMBOSIS; TRANSLATIONAL RESEARCH;

ANIMALS; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; BLOOD PLATELETS; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; PLATELET MEMBRANE GLYCOPROTEINS; SELEX APTAMER TECHNIQUE; THROMBIN; THROMBOPLASTIN; THROMBOSIS; TRANSLATIONAL RESEARCH; VON WILLEBRAND FACTOR;

EID: 79952780253     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-010-9230-6     Document Type: Review

References (65)

1. Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., et al. (2008). Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes*. Chest, 133, 670S-707S. doi:10.1378/chest.08-0691.
2. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001-2015. doi:10.1056/NEJMoa0706482. (Pubitemid 350106708)
3. Stone, G. W., Ware, J. H., Bertrand, M. E., Lincoff, A. M., Moses, J. W., Ohman, E. M., et al. (2007). Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA, 298, 2497-2506. doi:10.1001/jama.298.21.2497. (Pubitemid 350223536)
4. Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., et al. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, 373, 919-928.
5. Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage t4 DNA polymerase. Science, 249, 505-510.
6. Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
7. Dausse, E., Cazenave, C., Rayner, B., & Toulme, J. J. (2005). In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Methods in Molecular Biology, 288, 391-410.
8. Rimmele, M. (2003). Nucleic acid aptamers as tools and drugs: Recent developments. Chembiochem, 4, 963-971. doi:10.1002/cbic.200300648.
9. Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991). Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science, 253, 314-317. (Pubitemid 21917156)
10. Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., et al. (1995). Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. The Journal of Biological Chemistry, 270, 25702-25708.
11. Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005). Aptamers: An emerging class of therapeutics. Annual Review of Medicine, 56, 555-583. doi:10.1146/annurev.med.56.062904.144915. (Pubitemid 40299797)
12. Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010). Discovery and development of therapeutic aptamers. Annual Review of Pharmacology and Toxicology, 50, 237-257. doi:10.1146/annurev.pharmtox.010909.105547.
13. Rusconi, C. P., Yeh, A., Lyerly, H. K., Lawson, J. H., & Sullenger, B. A. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost, 84, 841-848.
14. Doudna, J. A., Cech, T. R., & Sullenger, B. A. (1995). Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proceedings of the National Academy of Sciences of the United States of America, 92, 2355-2359.
15. Lee, S. W., & Sullenger, B. A. (1997). Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnology, 15, 41-45. doi:10.1038/nbt0197-41.
16. Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., et al. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419, 90-94. (Pubitemid 34987876)
17. Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, G., et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnology, 22, 1423-1428. (Pubitemid 39482862)
18. Nimjee, S. M., Rusconi, C. P., Harrington, R. A., & Sullenger, B. A. (2005). The potential of aptamers as anticoagulants. Trends in Cardiovascular Medicine, 15, 41-45. (Pubitemid 40417544)
19. Chan, M. Y., Rusconi, C. P., Alexander, J. H., Tonkens, R. M., Harrington, R. A., & Becker, R. C. (2008). A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. Journal of Thrombosis and Haemostasis, 6, 789-796. (Pubitemid 351524539)
20. Oney, S., Lam, R. T., Bompiani, K. M., Blake, C. M., Quick, G., Heidel, J. D., et al. (2009). Development of universal antidotes to control aptamer activity. Nature Medicine, 15, 1224-1228.
21. Hoffman, M., Monroe, D. M., Oliver, J. A., & Roberts, H. R. (1995). Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 86, 1794-1801.
22. Monroe, D. M., Hoffman, M., & Roberts, H. R. (1996). Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Bood Coagulation and Fibrinolysis, 7, 459-464. (Pubitemid 26291519)
23. Howard, E. L., Becker, K. C. D., Rusconi, C. P., & Becker, R. C. (2007). Factor IXa inhibitors as novel anticoagulants. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 722-727. doi:10.1161/01.ATV.0000259363. 91070.f1. (Pubitemid 46606698)
24. Sramek, A., Kriek, M., & Rosendaal, F. (2003). Decreased mortality of ischaemic heart disease among carriers of haemophilia. Blood, 108, 52-66.
25. Tuinenburg, A., Mauser-Bunschoten, E., Verhaar, M., Biesma, D., & Schutgens, R. (2009). Cardiovascular disease in patients with hemophilia. Journal of Thrombosis and Haemostasis, 7, 247-254.
26. Bolton-Maggs, P. H. B., & Pasi, K. J. (2003). Haemophilias a and b. Lancet, 361, 1801-1809. (Pubitemid 36638432)
27. Dyke, C. K., Steinhubl, S. R., Kleiman, N. S., Cannon, R. O., Aberle, L. G., Lin, M., et al. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation, 114, 2490-2497. doi:10.1161/circulationaha.106.668434. (Pubitemid 44901522)
28. Nimjee, S. M., Keys, J. R., Pitoc, G. A., Quick, G., Rusconi, C. P., & Sullenger, B. A. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Molecular Therapy, 14, 408-415. (Pubitemid 44184966)
29. Chan, M. Y., Cohen, M. G., Dyke, C. K., Myles, S. K., Aberle, L. G., Lin, M., et al. (2008). Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation, 117, 2865-2874. doi:10.1161/circulationaha.107.745687. (Pubitemid 351787073)
30. Cohen, M. G., Purdy, D. A., Rossi, J. S., Grinfeld, L. R., Myles, S. K., Aberle, L. G., et al. (2010). First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation, 122, 614-622.
31. McLennan, D., Porter, C., Edwards, G., Martin, S., Heatherington, A., & Charman, S. (2005). Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. The Journal of Pharmacology and Experimental Therapeutics, 313, 345-351. (Pubitemid 40411360)
32. Rusconi, C. P., Kornbrust, D., & Zelenkofske, S. L. (2010). Subcutaneous FIXa inhibitor provides prolonged anticoagulation: the first successful subcutaneous application of an aptamer. Journal of the American College of Cardiology, 55, A172.E1618.
33. Zelenkofske, S., Rusconi, C. P., Damiento, C., Wargin, W., Medlock, M., Becker, R.C. (2010) Subcutaneous rb006: A direct FIXa inhibitor provides prolonged anticoagulation with rapid reversal: The first clinical experience with the reg2 system. Atherothrombosis and Vascular Biology Meeting, San Francisco, CA, April 5, 2010.
34. Eikelboom, J. W., Zelenkofske, S. L., & Rusconi, C. P. (2010). Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 382-387. doi:10.1161/atvbaha.110.203117.
35. Schwienhorst, A. (2006). Direct thrombin inhibitors - a survey of recent developments. Cellular and Molecular Life Sciences, 63, 2773-2791.
36. Bock, L., Griffin, L., Latham, J., Vermaas, E., & Toole, J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564-566.
37. DeAnda, A. J., Coutre, S., Moon, M., Vial, C., Griffin, L., Law, V., et al. (1994). Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. The Annals of Thoracic Surgery, 58, 344-350. (Pubitemid 24285100)
38. Buff, M. C. R., Schafer, F., Wulffen, B., Muller, J., Potzsch, B., Heckel, A., et al. (2010). Dependence of aptamer activity on opposed terminal extensions: Improvement of light-regulation efficiency. Nucleic Acids Research, 38, 2111-2118. doi:10.1093/nar/gkp1148.
39. Muller, J., Wulffen, B., Potzsch, B., & Mayer, G. (2007). Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. Chembiochem, 8, 2223-2226.
40. Jeter, M. L., Ly, L. V., Fortenberry, Y. M., Whinna, H. C., White, R. R., Rusconi, C. P., et al. (2004). RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Letters, 568, 10-14. (Pubitemid 38757946)
41. Long, S. B., Long, M. B., White, R. R., & Sullenger, B. A. (2008). Crystal structure of an RNA aptamer bound to thrombin. RNA, 14, 2504-2525.
42. Padmanabhan, K., Padmanabhan, K. P., Ferrara, J. D., Sadler, J. E., & Tulinsky, A. (1993). The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. The Journal of Biological Chemistry, 268, 17651-17654. (Pubitemid 23260263)
43. Padmanabhan, K., & Tulinsky, A. (1996). An ambiguous structure of a DNA 15-mer thrombin complex. Acta Crystallographica. Section D: Biological Crystallography, 52, 272-282.
44. Nimjee, S. M., Oney, S., Volovyk, Z., Bompiani, K. M., Long, S. B., Hoffman, M., et al. (2009). Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA, 15, 2105-2111.
45. De Meyer, S. F., Deckmyn, H., & Vanhoorelbeke, K. (2009). von Willebrand factor to the rescue. Blood, 113, 5049-5057. doi:10.1182/blood-2008- 10-165621.
46. Sadler, J. (2005). New concepts in von Willebrand disease. Annual Review of Medicine, 56, 173-191.
47. Sadler, J. (2005). von Willebrand factor: Two sides of a coin. Journal of Thrombosis and Haemostasis, 3, 1702-1709.
48. Ruggeri, Z. M. (2003). von Willebrand factor, platelets and endothelial cell interactions. Journal of Thrombosis and Jaemostasis, 1, 1335-1342.
49. Oney, S., Nimjee, S. M., Layzer, J., Que-Gewirth, N., Ginsburg, D., Becker, R. C., et al. (2007). Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides, 17, 265-274. doi:10.1089/oli.2007.0089. (Pubitemid 47463359)
50. Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., et al. (2007). First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 116, 2678-2686. doi:10.1161/circulationaha.107.724864. (Pubitemid 350291240)
51. Firbas, Cs., Jilma, B., Wagner, P. G., Hutabarat, R., Schaub, R. G., Gilbert, J. C., Knoebl, P. (2008) Anti von Willebrand factor aptamer arc 1779 for refractory thrombotic thrombocytopenic purpura. ASH Annual Meeting Abstracts 112, p. 2298
52. Ima, B. J., Jilma, P., Paulinska, P., Gilbert, J. C., Hutabarat, R., Wagner, T., Knoebl, P. (2008) Proof of concept for the anti von Willebrand factor aptamer in patients with relapsing thrombotic thrombocytopenic purpura (TTP). ASH Annual Meeting Abstracts 112, p. 2290
53. Jandrot-Perrus, M., Busfield, S., Lagrue, A.-H., Xiong, X., Debili, N., Chickering, T., et al. (2000). Cloning, characterization, and functional studies of human and mouse glycoprotein VI: A platelet-specific collagen receptor from the immunoglobulin superfamily. Blood, 96, 1798-1807. (Pubitemid 30661064)
54. Jung, S. M., Takemura, Y., Imamura, Y., Hayashi, T., Adachi, E., & Moroi, M. (2008). Collagen-type specificity of glycoprotein VI as a determinant of platelet adhesion. Platelets, 19, 32-42. (Pubitemid 351192835)
55. Arthur, J. F., Dunkley, S., & Andrews, R. K. (2007). Platelet glycoprotein VI-related clinical defects. British Journal Haematology, 139, 363-372. (Pubitemid 47515353)
56. Bigalke, B., Haap, M., Stellos, K., Geisler, T., Seizer, P., Kremmer, E., et al. (2010). Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thrombosis Research, 125, e184-e189.
57. Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M (2009) Glycoprotein VI for diagnosis of acute coronary syndrome when ECG is ambiguous. Int J Cardiol. doi:10.1016/j.ijcard.2009.12.026
58. Bigalke, B., Stellos, K., Geisler, T., Lindemann, S., May, A., & Gawaz, M. (2010). Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clinical Research in Cardiology, 99, 227-233.
59. Cabeza, N., Li, Z., Schulz, C., Kremmer, E., Massberg, S., Bultmann, A., et al. (2004). Surface expression of collagen receptor Fc receptor-γ/ glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes, 53, 2117-2121. doi:10.2337/diabetes.53.8.2117. (Pubitemid 38970763)
60. Denis, C. V., & Wagner, D. D. (2007). Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 728-739. doi:10.1161/01.atv.0000259359.52265.62. (Pubitemid 46606699)
61. Gawaz, M., Konrad, I., Hauser, A. I., Sauer, S., Li, Z., Wester, J.-J., et al. (2005). Non-invasive imaging of blycoprotein VI binding to injured arterial lesions. Thrombosis and Haemostasis, 93, 910-913. (Pubitemid 40691549)
62. Penz, S., Reininger, A. J., Brandl, R., Goyal, P., Rabie, T., Bernlochner, I., et al. (2005). Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. The FASEB Journal, 19, 898-909. doi:10.1096/fj.04-2748com. (Pubitemid 40827712)
63. De Meyer, S. F., Vanhoorelbeke, K., Ulrichts, H., Staelens, S., Feys, H., Salles, I., et al. (2006). Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovascular and Haematologic Disorders-Drug Targets, 6, 191-207. (Pubitemid 44377772)
64. Ohlmann, P., Hechler, B., Ravanat, C., Loyau, S., Herrenschmidt, N., Wanert, F., et al. (2008). Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. Thrombosis and Haemostasis, 6, 1003-1011. (Pubitemid 351689923)
65. Massberg, S., Konrad, I., Bultmann, A., Schulz, C., Munch, G., Peluso, M., et al. (2004). Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J., 18, 397-399. doi:10.1096/fj.03-0464fje.